Verastem Joins The Public Markets With A Strong IPO
This article was originally published in The Pink Sheet Daily
Executive Summary
Verastem IPO’d at $10 per share on Jan. 26, despite having only preclinical assets in its pipeline. Strong interest from large companies for cancer stem cell therapies helped contribute to the price.
You may also be interested in...
Ambit IPO Ambles Out; Portola And Bluebird Prepare
Despite pricing well below its range and trading down, Ambit could raise $90 million in an IPO and a private placement with existing investors. Also this week, gene therapy company bluebird bio filed for an IPO, and hematology play Portola made the rounds on its investor road show.
Biopharma IPOs Start to Gear Up For 2013 After a Lull
Biopharma and diagnostic IPOs have been relatively quiet since before the U.S. presidential election, but companies are again starting on road shows and updating prospectuses in anticipation of recaptured momentum.
Biopharma IPOs Start To Gear Up For 2013 After A Lull
Biopharma and diagnostic IPOs have been relatively quiet since before the U.S. presidential election, but companies are again starting on road shows and updating prospectuses in anticipation of recaptured momentum.